Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : TAK save search
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting - Apr 01, 2022
Published: 2022-04-01 (Crawled : 09:00) - biospace.com/
MNTS | $0.4609 -7.82% -8.48% 1.2M
|
|
| O: -0.31%
H: 3.14%
C: -0.94%
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.56%
H: 0.76%
C: 0.76%
Global Human Microbiome Therapeutic Market Set to Reach $3.4 Billion by 2030: Unleashing the Potential of Microbiome-based Therapies
Published: 2023-07-18 (Crawled : 02:00) - prnewswire.com
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.85%
H: 0.75%
C: 0.19%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.0%
H: 1.14%
C: -0.01%
DD | News | $73.8 -0.15% 0.0% 1.5M
|
Process Industries
|
| O: 0.7%
H: 2.13%
C: 2.0%
MCRB | $0.7629 22.14% 18.13% 12M
|
Health Technology
|
| O: -0.21%
H: 4.43%
C: 1.48%
EVLO | $0.3165 -87.39% 710K
|
Health Technology
|
| O: 4.79%
H: 63.71%
C: 54.3%
reach global set potential market
Exelixis Announces Second Quarter 2021 Financial Results and Provides Corporate Update
Published: 2021-08-05 (Crawled : 22:00) - biospace.com/
TEVA | $13.01 1.01% 0.0% 8.9M
|
Health Technology
|
| O: 0.5%
H: 2.84%
C: -0.7%
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.0%
H: 0.61%
C: 0.55%
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 0.26%
H: 0.13%
C: -0.36%
NKTR | News | $1.415 4.04% 3.89% 1.1M
|
Health Technology
|
| O: 0.77%
H: 1.33%
C: 0.83%
EXEL | $23.295 1.86% 1.82% 1.9M
|
Health Technology
|
| O: 0.0%
H: 2.03%
C: 1.25%
financial results results
PureTech Founded Entity Akili Announces Public Company Board of Director Nominees
Published: 2022-07-11 (Crawled : 12:00) - biospace.com/
DNAA 4 | $14.07 198.51%
|
|
| O: -0.1%
H: 0.1%
C: 0.0%
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.91%
H: 0.35%
C: -0.21%
SYBX | $1.9 3.26% 3.16% 66K
|
Health Technology
|
| O: 0.0%
H: 4.76%
C: 3.81%
NKTR | News | $1.415 4.04% 3.89% 1.1M
|
Health Technology
|
| O: -0.26%
H: 1.83%
C: -7.59%
KRTX | $329.83 0.0% 1.9M
|
Health Technology
|
| O: -0.25%
H: 0.59%
C: -5.03%
ADXN | $19.28 -10.32% 13K
|
Health Technology
|
| O: -3.68%
H: 10.48%
C: 3.23%
Natural Killer (NK) Cell Therapeutics Market to Perceive Healthy CAGR of 40.9% by 2029, Size, Share, Trends, Demand, Opportunities, Challenges and Competitive Analysis
Published: 2022-11-28 (Crawled : 07:00) - prnewswire.com
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: -0.62%
H: 1.04%
C: 0.41%
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 0.05%
H: 0.53%
C: -0.18%
NKTX | $7.55 2.17% 2.12% 710K
|
Health Technology
|
| O: -0.46%
H: 2.09%
C: -6.26%
NKTR | News | $1.415 4.04% 3.89% 1.1M
|
Health Technology
|
| O: -0.62%
H: 1.09%
C: -3.73%
therapeutics market
Syros Announces Appointment of Deborah Dunsire, M.D., to Its Board of Directors
Published: 2021-09-10 (Crawled : 13:15) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.35%
H: 0.06%
C: -0.88%
RARE F | $45.06 3.14% 3.04% 840K
|
Health Technology
|
| O: 0.23%
H: 1.2%
C: 0.22%
SYRS | $5.17 3.61% 3.48% 170K
|
Health Technology
|
| O: 0.76%
H: 0.0%
C: -4.7%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: 0.04%
H: 0.84%
C: -2.2%
Arrowhead Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease
Published: 2021-04-28 (Crawled : 13:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: -0.95%
H: 0.84%
C: 0.48%
ARWR | $23.775 -0.61% -0.61% 830K
|
Health Technology
|
| O: 0.01%
H: 2.92%
C: 1.92%
disease liver disease treatment fibrosis liver
Arrowhead Pharmaceuticals Reports Fiscal 2021 Second Quarter Results
Published: 2021-05-04 (Crawled : 21:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: -1.25%
ARWR | $23.775 -0.61% -0.61% 830K
|
Health Technology
|
| O: -3.13%
H: 2.97%
C: -2.29%
results
Arrowhead Pharmaceuticals Reports Fiscal 2021 Third Quarter Results
Published: 2021-08-05 (Crawled : 22:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.0%
H: 0.61%
C: 0.55%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: -0.09%
ARWR | $23.775 -0.61% -0.61% 830K
|
Health Technology
|
| O: -0.27%
H: 4.66%
C: 3.2%
results
Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver Disease
Published: 2021-07-29 (Crawled : 20:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.0%
H: 0.06%
C: -1.17%
ARWR | $23.775 -0.61% -0.61% 830K
|
Health Technology
|
| O: 1.95%
H: 1.82%
C: -1.98%
disease liver disease treatment fda therapy breakthrough therapy liver designation
Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment at AASLD Liver Meeting
Published: 2021-11-12 (Crawled : 13:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
ARWR | $23.775 -0.61% -0.61% 830K
|
Health Technology
|
| O: -1.54%
H: 0.0%
C: 0.0%
treatment liver
Arrowhead Pharmaceuticals Reports Fiscal 2022 First Quarter Results
Published: 2022-02-02 (Crawled : 00:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: -0.21%
H: 0.0%
C: 0.0%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -0.99%
H: 0.0%
C: 0.0%
ARWR | $23.775 -0.61% -0.61% 830K
|
Health Technology
|
| O: 0.2%
H: 0.0%
C: 0.0%
als report results
Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine
Published: 2022-06-27 (Crawled : 11:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 1.09%
H: 1.36%
C: 0.93%
ARWR | $23.775 -0.61% -0.61% 830K
|
Health Technology
|
| O: 0.55%
H: 1.01%
C: -2.68%
results phase 2
Global Hereditary Angioedema Market to Surpass US$ 4,897.51 Million by 2030 - Coherent Market Insights
Published: 2022-08-23 (Crawled : 19:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -4.66%
H: 0.0%
C: -1.69%
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: -0.79%
H: 0.98%
C: 0.72%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -1.48%
H: 0.0%
C: 0.0%
IONS | $41.85 1.9% 1.86% 630K
|
Health Technology
|
| O: 0.71%
H: 2.81%
C: 1.31%
CNTG | $0.504 7.21% 6.73% 72K
|
Commercial Services
|
| O: 3.33%
H: 0.0%
C: -3.87%
BCRX | News | $4.375 -0.79% -0.8% 4.2M
|
Health Technology
|
| O: -0.97%
H: 5.66%
C: 3.49%
ARWR | $23.775 -0.61% -0.61% 830K
|
Health Technology
|
| O: 0.32%
H: 4.28%
C: 3.39%
ADVM | News | $10.96 -3.35% -3.47% 310K
|
Health Technology
|
| O: -1.6%
H: 4.07%
C: 1.63%
global market hereditary angioedema
Outlook on the Hereditary Angioedema Global Market to 2030 - Size, Share, Outlook, and Opportunity Analysis
Published: 2022-09-05 (Crawled : 11:00) - prnewswire.com
CNTG | $0.504 7.21% 6.73% 72K
|
Commercial Services
| Email alert
Add to watchlist
ADVM | News | $10.96 -3.35% -3.47% 310K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
| Email alert
Add to watchlist
IONS | $41.85 1.9% 1.86% 630K
|
Health Technology
| Email alert
Add to watchlist
BCRX | News | $4.375 -0.79% -0.8% 4.2M
|
Health Technology
| Email alert
Add to watchlist
ARWR | $23.775 -0.61% -0.61% 830K
|
Health Technology
| Email alert
Add to watchlist
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
| Email alert
Add to watchlist
global market hereditary angioedema
Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Published: 2023-01-09 (Crawled : 13:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.13%
H: 0.38%
C: -0.19%
ARWR | $23.775 -0.61% -0.61% 830K
|
Health Technology
|
| O: -19.61%
H: 3.16%
C: 0.77%
liver disease topline results study
First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to Arrowhead
Published: 2023-04-04 (Crawled : 17:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: -0.12%
H: 1.55%
C: 1.03%
ARWR | $23.775 -0.61% -0.61% 830K
|
Health Technology
|
| O: 0.67%
H: 0.08%
C: -2.22%
liver disease payment milestone study
Arrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter Results
Published: 2023-08-07 (Crawled : 21:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.62%
H: 0.62%
C: 0.42%
GSK | News | $41.24 1.6% 0.0% 2.3M
|
Health Technology
|
| O: 0.35%
H: 0.41%
C: 0.41%
ARWR | $23.775 -0.61% -0.61% 830K
|
Health Technology
|
| O: 0.0%
H: 0.44%
C: -2.65%
pharmaceuticals results
Poseida Therapeutics Announces Research Collaboration with Takeda for Novel Non-Viral In Vivo Gene Therapies
Published: 2021-10-12 (Crawled : 14:15) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.21%
H: 0.14%
C: -1.05%
PSTX | $2.15 -0.23% -0.23% 420K
|
Health Technology
|
| O: 5.26%
H: 0.5%
C: -4.57%
gene therapies collaboration research gene therapy therapy
Poseida Therapeutics to Host Virtual R&D Day on February 23, 2022
Published: 2022-02-09 (Crawled : 14:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.13%
H: 0.4%
C: -0.13%
PSTX | $2.15 -0.23% -0.23% 420K
|
Health Technology
|
| O: -2.1%
H: 0.0%
C: 0.0%
day therapeutics
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.